|
|
|
| The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis |
| He-Li Gao a,b,c,d, Liang Liu a,b,c,d, Zi-Hao Qi a,b,c,d, Hua-Xiang Xu a,b,c,d, Wen-Quan Wang a,b,c,d, Chun-Tao Wu a,b,c,d, Shi-Rong Zhang a,b,c,d, Jin-Zhi Xu a,b,c,d, Quan-Xing Ni a,b,c,d, Xian-Jun Yu a,b,c,d,∗ |
a Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China
b Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
c Shanghai Pancreatic Cancer Institute, Shanghai 200032, China
d Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China
∗ Corresponding author at: Department of Pancreatic Surgery, Fudan University
Shanghai Cancer Center, Shanghai 200032, China.
E-mail addresses: yuxianjun@fudanpci.org, yuxianjun@fudan.edu.cn (X.-J. Yu). |
|
|
|
Abstract BACKGROUND: Immunotherapy has shown promise against solid tumors. However, the clinical significance of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) in pancreatic ductal adenocarcinoma (PDAC) remains unclear. This meta-analysis aimed to analyze the prognostic effect of PD-L1 in PDAC.
DATA SOURCES: Electronic search of the PubMed, Cochrane Library and Web of Science was performed until December 2016. Through database searches, we identified articles describing the relationship between PD-L1 status and PDAC patient prognosis. Meta-analysis was performed to investigate the relationship between PD-1 and overall survival (OS).
RESULTS: Nine studies with 989 PDAC patients were included for PD-L1 expression analysis. And 5 studies with 688 PDAC patients were included in the prognostic analysis. The PD-L1 positive rate measured by immunohistochemistry (IHC) was higher than that measured by polymerase chain reaction (PCR) (P?<?0.001). PDAC patients with high expression levels of PD-L1 had significantly reduced OS (HR?=?2.34; 95% CI: 1.78-3.08). Subgroup analysis showed that the prognostic effect of PD-L1 levels was similar between the IHC and PCR methods. The PD-L1 positive rate was associated with PDAC T stages; the PD-L1 positive rate in the T3-4 group was higher than that in the T1-2 group (OR?=?0.37; P?=?0.001).
CONCLUSIONS: High PD-L1 expression levels predicted a poor prognosis in PDAC patients. Thus, PD-L1 status helps determine treatment in PDAC patients.
|
|
|
|
|
|
|
|
|
2018, Vol. 17 
